Advancing Bispecific and Combination Therapy to the Clinic focuses on novel concepts and their developments. Presentations will include synergistic combinations together with their rationale and provide data showing improved performance, including potency, targeting, stability, half-life and reduced toxicity. Preclinical studies leading up to proof-of-concept and IND enabling studies will be included as well as developments up to phases 2 and 3 for the more advanced products.

Preliminary Agenda

NEW APPROACHES TO DEVELOPMENT

KEYNOTE PRESENTATION: Bispecific Antibody; Discovery, Development and Next Generation

Tomoyuki Igawa, PhD, CEO, Head, Research, Global Biologics Leader, Chugai Pharmabody Research Pte. Ltd.

Engineering and Development of a T Cell Bispecific for Colorectal Cancer

Adam Root, PhD, Senior Principal Scientist, Global Biotherapeutics, Pfizer, Inc.

Targeting Cancer with BiTE® Antibody Constructs

Roman Kischel, MD, Director, Research, Amgen Research (Munich) GmbH

BISPECIFICS FOR T-CELL ENGAGEMENT DEMONSTRATING SUPERIOR PROPERTIES

Progress with Bispecific Vγ9Vδ2-T Cell Engagers

Paul W.H.I. Parren, PhD, Executive Vice President, Head, R&D Lava Therapeutics B.V.

Preclinical Combinations of T Cell Bispecifics Targeting Solid Tumors and Hematological Malignancies

Marina Bacac, PhD, Head, Cancer Immunotherapy Department 2 (CIT-2), Roche Innovation Center Zurich

A Novel Mucin 16 Bispecific T Cell Engaging Antibody for the Treatment of Ovarian Cancer

Alison Crawford, PhD, Senior Staff Scientist, Oncology and Angiogenesis, Regeneron Pharmaceuticals, Inc.

The Journey to 'the' Antibody: Tailoring for Success

María González Pajuelo, CSO, FairJourney Biologics


OVERCOMING PROBLEMS ARISING IN THE CLINIC / CYTOKINE RELEASE ASSAYS

Problems that Arise in the Clinic Regarding TME, Immuno-Suppression and T Cell Exhaustion

Tariq Ghayur, PhD, Distinguished Research Fellow, Abbvie Bioresearch

An International Collaborative Study to Establish a 1st Reference Panel for Cytokine Release Assays

Sandrine Vessillier, PhD, Principal Scientist, Head, Immunotoxicology Cellular Immunology, Biotherapeutics, National Institute for Biological Standards and Control, UK

INNOVATIVE PLATFORMS YIELDING PRODUCTS HEADING FOR THE CLINIC

DuoHexaBody-CD37, a Novel CD37-Targeting Bispecific Antibody with a Hexamerization-Enhancing Mutation, Demonstrating Superior Preclinical Activity Against Malignant B Cells in vitro, ex vivo and in vivo

Laurens Kil, PhD, Senior Scientist, Genmab B.V.

Towards RNA-Based Cancer Immunotherapy: Advances in the Development of mRNA Encoded Therapeutic Antibodies

Ursula Ellinghaus, PhD, Scientist, Bispecific Antibodies, BioNTech RNA Pharmaceuticals GmbH

Anticalin Proteins and their Application in Respiratory Disease

Christine Rothe, PhD, VP, Discovery & Alliance Management, Pieris Pharmaceuticals GmbH

BISPECIFICS FOR CHECKPOINT INHIBITORS TOGETHER WITH ANTAGONISTS OR AGONISTS

Design Meets Biology – Engineering a PD-1/CTLA-4 Bispecific Antibody to Improve Both Safety and Efficacy

Yariv Mazor, PhD, Senior Scientist, Antibody Discovery & Protein Engineering, MedImmune, LLC

PD-1 x LAG-3 (MGD013) and PD-1 x CTLA-4 (MGD019): Two Clinical-Stage DART® Molecules Designed to Simultaneously Block Two Checkpoint Pathways

Alexey Berezhnoy, PhD, Scientist, Cell Biology & Immunology, MacroGenics, Inc.

A Novel, Monovalent Tri-Specific Antibody-Based Molecule that Simultaneously Modulates PD-L1 and 4-1BB Exhibits Potent Anti-Tumoral Activity in vivo

Sebastian Meyer, PhD, COO, Numab Innovation AG

SCREENING AND IDENTIFICATION OF BISPECIFIC AND NON-BISPECIFIC COMBINATIONS

Unbiased Functional Screening of Large Bispecific Antibody Panels to Unlock Novel Biology

Pieter Fokko van Loo, PhD, Director, Oncology-Immunology, Merus N.V.

Benefits of Chicken-Derived Antibodies for Combination Immunotherapy

Klaus Koefoed, PhD, MSc, Director, Antibody Technology, Symphogen A/S



* The program is subject to change without notice, due to unforeseen reason.


Choose your language
Japanese
Traditional Chinese
Simplified Chinese
Korean